http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 10 Aug 2026 04:13:41 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Increasing+unusual+option+volume%3A+STLN+REAL+EWC+DOCS+OMF+WWR+HTZ+ARDX+/26893068.html <p>Increasing unusual option volume: STLN REAL EWC DOCS OMF WWR HTZ ARDX</p> http://www.streetinsider.com/Options/Increasing+unusual+option+volume%3A+STLN+REAL+EWC+DOCS+OMF+WWR+HTZ+ARDX+/26893068.html Mon, 10 Aug 2026 04:13:41 -0400 STLN http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html si-local-file:///var/storage/secattach/20260806/26884895.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html Thu, 06 Aug 2026 16:36:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html si-local-file:///var/storage/secattach/20260806/26884895.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html Thu, 06 Aug 2026 16:36:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html si-local-file:///var/storage/secattach/20260806/26884895.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Starling+Oncology%2C+Inc.+++For%3A+Jun+30/26884895.html Thu, 06 Aug 2026 16:36:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html si-local-file:///var/storage/secattach/20260806/26884805.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html Thu, 06 Aug 2026 16:33:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html si-local-file:///var/storage/secattach/20260806/26884805.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html Thu, 06 Aug 2026 16:33:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html si-local-file:///var/storage/secattach/20260806/26884805.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Starling+Oncology%2C+Inc.+++For%3A+Aug+06/26884805.html Thu, 06 Aug 2026 16:33:00 -0400 O.21802973 STLN TOI http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Press+Releases/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html <p align="justify">CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it&apos;s full-year 2026 guidance.</p> <p align="justify"><strong>Recent Operational Highlights</strong></p> <ul type="disc"><li style="text-align:left;">Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the http://www.streetinsider.com/Globe+Newswire/Starling+Oncology+Reports+Second+Quarter+2026+Financial+Results+and+Updates+Full-Year+2026+Guidance/26883941.html Thu, 06 Aug 2026 16:14:00 -0400 O.21802973 STLN TOI TOIIW http://www.streetinsider.com/Press+Releases/The+Oncology+Institute+Rebrands+as+Starling+Oncology/26854045.html <p><strong>Company to begin trading on Nasdaq under new ticker symbol “STLN,” replacing “TOI”</strong></p><p>CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to “Starling Oncology, Inc.™.” The Company's common stock will begin trading under the new ticker symbol "STLN” on Nasdaq, effective August 4, 2026, replacing its previous ticker symbol “TOI.”</p> <p>“We've spent the past several years rebuilding this organization, reaching profitability, and scaling a technology-enabled, highly coordinated care model. We have proven that http://www.streetinsider.com/Press+Releases/The+Oncology+Institute+Rebrands+as+Starling+Oncology/26854045.html Mon, 03 Aug 2026 08:00:00 -0400 STLN http://www.streetinsider.com/Globe+Newswire/The+Oncology+Institute+Rebrands+as+Starling+Oncology/26854045.html <p><strong>Company to begin trading on Nasdaq under new ticker symbol “STLN,” replacing “TOI”</strong></p><p>CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to “Starling Oncology, Inc.™.” The Company's common stock will begin trading under the new ticker symbol "STLN” on Nasdaq, effective August 4, 2026, replacing its previous ticker symbol “TOI.”</p> <p>“We've spent the past several years rebuilding this organization, reaching profitability, and scaling a technology-enabled, highly coordinated care model. We have proven that http://www.streetinsider.com/Globe+Newswire/The+Oncology+Institute+Rebrands+as+Starling+Oncology/26854045.html Mon, 03 Aug 2026 08:00:00 -0400 STLN